ISSN 1662-4009 (online)

ey0017.10-10 | (1) | ESPEYB17

10.10. ‘I’m essentially his pancreas’: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes

PV Commissariat , KR Harrington , AL Whitehouse , KM Miller , ME Hilliard , M Van Name , DJ DeSalvo , WV Tamborlane , BJ Anderson , LA DiMeglio , LM Laffel

To read the full abstract: Pediatr Diabetes. 2020 Mar;21(2):377–383. doi: 10.1111/pedi.12956. PMID: 31808586Across all age groups, management of type 1 diabetes (T1DM) places substantial workload, responsibility and emotional burden, such as worries and stress, on families. This study explored parent perceptions of the burdens of caring for very young children with T1DM. Semi-structured qu...

ey0017.10-8 | (1) | ESPEYB17

10.8. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

KC Herold , BN Bundy , SA Long , JA Bluestone , LA DiMeglio , MJ Dufort , SE Gitelman , PA Gottlieb , JP Krischer , PS Linsley , JB Marks , W Moore , A Moran , H Rodriguez , WE Russell , D Schatz , JS Skyler , E Tsalikian , DK Wherrett , AG Ziegler , CJ Greenbaum , Type 1 Diabetes TrialNet Study Group

To read the full abstract: N Engl J Med. 2019 Aug 15;381(7):603–613. doi: 10.1056/NEJMoa 1902226.Type 1 diabetes (T1DM) is a chronic autoimmune disease that leads to destruction of insulin producing beta cells, which leaves the patient dependent on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in T1DM, but interventions to prevent clinic...

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 7–17 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...